Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing immuno-oncology and dermatology therapies. Founded in 2012 and headquartered in Wayne, Pennsylvania, the company is known for its focus on immune-mediated diseases and dermatological conditions, leveraging innovative small molecule and antibody-based approaches.
Company News
Aclaris Therapeutics will present additional results from its Phase 2a trial of ATI-2138, an investigational oral drug targeting ITK and JAK3, at the 2025 European Academy of Dermatology and Venereology Congress in Paris.
Insiders have been buying shares in several penny stocks, including Branchout Food, Innovative Food Holdings, Crown Equity Holdings, and Aclaris Therapeutics. The insider purchases indicate their confidence in the companies' prospects.
Aclaris (ACRS) delivered earnings and revenue surprises of 14.29% and 20.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Penny Stocks – How News Makes These Small Caps Soar or Plunge… The post Best Penny Stocks To Buy? 4 To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
A bull on the company became more positive on its prospects.